In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 3; pp. 1847 - 1853
• Main Authors: Cheng, Guofeng, Tian, Yang, Doehle, Brian, Peng, Betty, Corsa, Amoreena, Lee, Yu-Jen, Gong, Ruoyu, Yu, Mei, Han, Bin, Xu, Simin, Dvory-Sobol, Hadas, Perron, Michel, Xu, Yili, Mo, Hongmei, Pagratis, Nikos, Link, John O, Delaney, William
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.03.2016
• Subjects: Antiviral Agents; Antiviral Agents - pharmacology; Benzimidazoles; Benzimidazoles - pharmacology; Carrier Proteins - antagonists & inhibitors; Cell Line, Tumor; Drug Combinations; Drug Resistance, Viral - genetics; Drug Synergism; Fluorenes; Fluorenes - pharmacology; Genotype; HeLa Cells; Hepacivirus; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C, Chronic; Hepatitis C, Chronic - drug therapy; Humans; Intracellular Signaling Peptides and Proteins; Microbial Sensitivity Tests; Sofosbuvir - pharmacology; Viral Nonstructural Proteins; Viral Nonstructural Proteins - antagonists & inhibitors
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.02524-15

Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activity in combination with other anti-HCV agents. LDV has picomolar antiviral activity against genotype 1a and genotype 1b replicons with 50% effective concentration (EC50) values of 0.031 nM and 0.004 nM, respectively. LDV is also active against HCV genotypes 4a, 4d, 5a, and 6a with EC50 values of 0.11 to 1.1 nM. LDV has relatively less in vitro antiviral activity against genotypes 2a, 2b, 3a, and 6e, with EC50 values of 16 to 530 nM. In vitro resistance selection with LDV identified the single Y93H and Q30E resistance-associated variants (RAVs) in the NS5A gene; these RAVs were also observed in patients after a 3-day monotherapy treatment. In vitro antiviral combination studies indicate that LDV has additive to moderately synergistic antiviral activity when combined with other classes of HCV direct-acting antiviral (DAA) agents, including NS3/4A protease inhibitors and the nucleotide NS5B polymerase inhibitor SOF. Furthermore, LDV is active against known NS3 protease and NS5B polymerase inhibitor RAVs with EC50 values equivalent to those for the wild type.